DelveInsight’s Burkitt lymphoma Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Burkitt lymphoma, historical and forecasted epidemiology as well as the Burkitt lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Burkitt lymphoma is a form of non-Hodgkin’s lymphomas (NHLs) which are a group of blood cancers derived from lymphocytes. Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin’s lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated.
Some facts of Burkitt lymphoma Market are:
- According to WebMD, in the United States, around 1,200 new cases are diagnosed each year.
- Burkitt Lymphoma Society, the condition accounts for around 40% of the childhood non-Hodgkin lymphoma cases globally.
- It also accounts for as many as 40% of all non-Hodgkin lymphomas in HIV/AIDS patients.
- Burkitt lymphoma (BL) may be defined as an aggressive rare disorder that constitutes approximately 1% to 2% of all non-Hodgkin lymphomas.
- Burkitt lymphoma is known as one of the most aggressive forms of lymphoma, with a doubling time of approximately 24 hours.
- According to the Cancer Research UK, 2015, around 200,000 new cases and over 140,000 deaths are estimated to be recorded each year due to EBV-associated cancers.
- According to the survey conducted by WebMD, LLC, in 2015, around 1,200 people are diagnosed each year in the U.S., of which around 59% are aged 40 years and above.
- According to the survey by Lymphoma Action Organization, 2015, around 210 people are affected by Burkitt lymphoma every year in the U.K.
Request for Sample Report: https://www.delveinsight.com/sample-request/burkitt-lymphoma-market
Scope of the Burkitt lymphoma Market Report
- The report covers the descriptive overview of Burkitt lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Burkitt lymphoma epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Burkitt lymphoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Burkitt lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Burkitt lymphoma market
Request for Sample Report: https://www.delveinsight.com/sample-request/burkitt-lymphoma-market
Some Burkitt lymphoma Companies are:
- Takeda Pharmaceutical
- Novartis AG
- Seattle Genetics, Inc
- Sanofi
- Mayo Clinic
- MethylGene Inc
- Eisai Inc
- Cellerant Therapeutics
- And Many Others
Some Burkitt lymphoma Therapies are:
- RITUXIMAB
- SGN-CD19A
- Alisertib
- Clofarabine
- And Many Others
Request for Sample Report: https://www.delveinsight.com/sample-request/burkitt-lymphoma-market
Table of Contents:
1. Key Insights
2. Executive Summary of Burkitt lymphoma
3. Competitive Intelligence Analysis for Burkitt lymphoma
4. Burkitt lymphoma: Market Overview at a Glance
4.1. Burkitt lymphoma Total Market Share (%) Distribution in 2018
4.2. Burkitt lymphoma Total Market Share (%) Distribution in 2030
5. Burkitt lymphoma: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Burkitt lymphoma Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Burkitt lymphoma Epidemiology Scenario in the 7MM (2018-2030)
7.4. United States Epidemiology
7.4.1. Burkitt lymphoma Epidemiology Scenario in the United States (2018-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Burkitt lymphoma Epidemiology Scenario in Germany (2018-2030)
7.5.2. France Epidemiology
7.5.2.1. Burkitt lymphoma Epidemiology Scenario in France (2018-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Burkitt lymphoma Epidemiology Scenario in Italy (2018-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Burkitt lymphoma Epidemiology Scenario in Spain (2018-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Burkitt lymphoma Epidemiology Scenario in the United Kingdom (2018-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Burkitt lymphoma Epidemiology Scenario in Japan (2018-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Burkitt lymphoma Treatment and Management
8.2. Burkitt lymphoma Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Burkitt lymphoma Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Burkitt lymphoma: Seven Major Market Analysis
13.1. Key Findings
13.2. Burkitt lymphoma Market Size in 7MM
13.3. Burkitt lymphoma Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Burkitt lymphoma Total Market Size in the United States
15.1.2. Burkitt lymphoma Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Burkitt lymphoma Total Market Size in Germany
15.3.2. Burkitt lymphoma Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Burkitt lymphoma Total Market Size in France
15.4.2. Burkitt lymphoma Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Burkitt lymphoma Total Market Size in Italy
15.5.2. Burkitt lymphoma Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Burkitt lymphoma Total Market Size in Spain
15.6.2. Burkitt lymphoma Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Burkitt lymphoma Total Market Size in the United Kingdom
15.7.2. Burkitt lymphoma Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Burkitt lymphoma Total Market Size in Japan
15.8.3. Burkitt lymphoma Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Burkitt lymphoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/burkitt-lymphoma-market